UK Biobank offers its wares as Prof Rawlins takes the chair
This article was originally published in Clinica
Researchers from industry and academia alike are now able to access the information stored in the not-for-profit UK Biobank. In addition, Professor Sir Mike Rawlins, chair of the UK's National Institute of Health and Clinical Excellence (NICE), has been announced as chairman of the organisation, replacing Sir Alan Langlands, chief executive of the Higher Education Funding Council for England, and former CEO of the NHS, who over the past eight years has steered the project through its establishment and early phases.
You may also be interested in...
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.